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Abstract
The vectorization of rare human adenovirus (HAdV) types will widen our knowledge of this family and their interaction with
cells, tissues and organs. In this study we focus on HAdV-56, a member of human Ad species D, and create ease-of-use
cloning systems to generate recombinant HAdV-56 vectors carrying foreign genes. We present in vitro transduction profiles
for HAdV-56 in direct comparison to the most commonly used HAdV-5-based vector. In vivo characterizations demonstrate
that when it is delivered intravenously (i.v.) HAdV-56 mainly targets the spleen and, to a lesser extent, the lungs, whilst
largely bypassing liver transduction in mice. HAdV-56 triggered robust inflammatory and cellular immune responses, with
higher induction of IFNg, TNFa, IL5, IL6, IP10, MCP1 and MIG1 compared to HAdV-5 following i.v. administration. We also
investigated its potential as a vaccine vector candidate by performing prime immunizations in mice with HAdV-56 encoding
luciferase (HAdV-56-Luc). Direct comparisons were made to HAdV-26, a highly potent human vaccine vector currently in
phase II clinical trials. HAdV-56-Luc induced luciferase ‘antigen’-specific IFNg-producing cells and anti-HAdV-56 neutralizing
antibodies in Balb/c mice, demonstrating a near identical profile to that of HAdV-26. Taken together, the data presented
provides further insight into human Ad receptor/co-receptor usage, and the first report on HAdV-56 vectors and their
potential for gene therapy and vaccine applications.
INTRODUCTION
Decades of research into the family Adenoviridae has, for
the most part, focused on human Ad type 5 (HAdV-5) as
a prototype vector, with this providing the basis of our
knowledge of Ad receptor/co-receptor usage, host interac-
tions and immunogenicity. HAdV-5 has many desirable
attributes, including ease of genetic manipulation, efficient
production systems and the detailed characterization of its
infection profiles. Despite the accumulation of years of
clinical trial safety data, the evidence for therapeutic effi-
cacy has been questionable, and this is in large part due to
high levels of neutralizing antibodies against HAdV-5 in
the general population capable of minimizing the active
vector load, and/or poor or irregular expression and expo-
sure of its cellular receptor [coxsackie and adenovirus
receptor (CAR)] on cells and tissues of interest [1]. Given
the large number of other Ad types available, the recent
advances in DNA manipulation technologies and the con-
venience of CRISPR genome editing, there is significant
interest in developing new viral vector strategies [2–6].
There is a need to find Ad types with low seroprevalence
and alternative tropisms in place of HAdV-5, but without
compromising on the ease of manufacture and vector yield
[7, 8]. Thus investigation into the in vitro and in vivo
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biology of less prevalent virus types may advance the clini-
cal use of Ad-based platforms.
HAdV species D (HAdV-D) is the largest of the seven
human species, but very few of these Ads have been exploited
as potential clinical tools. Most HAdVs belonging to other
species use CD46, CAR or desmoglein 2 (DSG2) as high-
affinity primary receptors for viral fibre proteins, and av-
integrins as co- or internalization receptors (referred to
below solely as co-receptors) for viral penton base proteins
[9]. Specific members of species D HAdV are reported to
also use sialic acid-containing receptors and in particular a
sialic acid-containing hexasaccharide that is identical to that
of GD1a gangliosides [10–12]. In direct contrast to HAdV-5,
the absence of pre-existing immunity to rare HAdV-D types
[13] makes them good candidates for gene therapy or vac-
cine regimes. Here, we focus on a more recently discovered
HAdV-D, Ad type 56 (HAdV-56), a member of the small
subgroup of Ad causing the severe and highly contagious
ocular infection known as epidemic keratoconjunctivitis
(EKC). Whilst the complete genomic sequence for HAdV-56
is available (GenBank accession no. HM770721.2), import-
ant aspects of its biology and therapeutic applications remain
unexplored. The arguments to investigate this virus stand on
its predicted low seroprevalence, as HAdV-56 has a chimae-
ric hexon comprising rare HAdV-15 and HAdV-29 viruses
with a fibre protein that is most similar to HAdV-9 [14].
Furthermore, the ability of HAdV-56 to cause potent infec-
tions with marked ocular tropism suggests that it may use
non-classical receptors/co-receptors or possess interesting
immune modulatory elements [14]. In the present study we
generate novel E1/E3-deleted, replication-deficient reporter
vectors based on HAdV-56 as tools to study its biology.
These recombinant HAdV-56 (rHAdV-56) vectors are used
to characterize the seroprevalence, receptor/co-receptor
usage and tropism of their parental serotype, while we also
provide valuable information on the potential of HAdV-56
as a vascular gene therapy and vaccine vector.
RESULTS
Generation of replication-deficient HAdV-56 vectors
expressing reporter genes
We first generated HAdV-56 vectors expressing reporter
genes to enable us to study the virus biology and its therapeu-
tic applicability efficiently. To produce replication-incompe-
tent reporter viruses, the E1 gene of HAdV-56 was replaced
with luciferase, GFP or LacZ in a shuttle plasmid containing
a multiple cloning site for the easy insertion of foreign genes.
The E3 region was also deleted to increase transgene packag-
ing capacity. To enhance the potential for viral propagation
in a standard producer cell line, the HAdV-56 E4ORF6
region was exchanged with that of HAdV-5, as this strategy
was previously reported to enhance the growth of recombi-
nant Ad vectors in HAdV-5 E1-complementing HEK293
cells [15, 16]. A schematization of the cloning system
and HAdV-56 vector (rHAdV-56.DE1.DE3.Ad5.E4ORF6)
genome organization is shown in Fig. 1. At approximately
14 days post-co-transfection of HAdV-56-based plasmids,
cytopathic effect (CPE) was observed and viral progeny were
successfully propagated. The resulting vectors were verified
by DNA sequencing and all were found to express their cor-
responding transgene efficiently, as assessed by luciferase
assay, fluorescence microscopy and b-galactosidase staining
of HAdV-56-Luc-, HAdV-56-GFP- and HAdV-56-LacZ-
infected cells, respectively. All vectors were grown to high
titres and good quality purified vector batches were pro-
duced by standard CsCl purification systems (see Fig. S1,
available in the online version of this article for silver stain
andWestern blot analysis).
Manufacture of HAdV-56 vectors
During the preclinical development stage it is important to
consider whether the vector of interest is amenable to
manufacturing protocols and the rigorous quality controls
required in cases of clinical translation. Even though
manufacturing systems are developed for the HAdV-5-
based vectors that are used as standard, such systems do not
always work as well for other Ad vectors. In order to investi-
gate whether the HAdV-56 vectors could also be produced
and purified utilizing such manufacturing procedures,
HEK293 suspension cells were infected with rHAdV-56 uti-
lizing GMP-compliant and commercially available media
(EX-CELL 293, AEM, CD293, CDM4-HEK293, SFM4-
HEK293 and EX-CELL GTM-3) at cell densities of 1.5106
cellsml 1. All of the tested media showed comparable log10
TCID50 ml
 1 yields (8.39 to 9.54) (Fig. S1b). Traditionally,
Ad vectors are purified using Mustang Q filters as the first
capture step. Therefore we investigated whether Mustang Q
filters are a suitable capture entity for rHAdV-56, and
broadened the investigation by looking at alternative filters
such as Poros HQ and Monolith QA. All of the tested enti-
ties worked well for the rHAdV-56 capture purification
step, but our results indicate that Poros HQ has the best
recovery and purity (Fig. S1c–e). Looking at these
manufacturing parts, we conclude that rHAdV-56 can be
produced to high titres and then purified to a high degree of
purity in manufacturing settings, an essential criterion for
the large-scale GMP production required for many clinical
applications.
Characterization of HAdV-56 receptor/co-receptor
usage
Unlike the well-studied Ad gene therapy or vaccination
vectors (e.g. HAdV-5, HAdV-26 and HAdV-35), HAdV-
56 belongs to a small group of Ad-Ds that have been
reported to be causative agents of EKC, which is sugges-
tive of alternative infection profiles and potentially differ-
ent entry receptors/co-receptors. Being associated with
ocular, respiratory and urinary tract disease [17–20],
HAdV-56 infection of corneal cells has been documented
[20], but studies investigating the transduction of other
cell types and receptor/co-receptor usage are limited.
Therefore the transduction capacity of the novel HAdV-56
vectors was assessed in the classical CAR-abundant lung
adenocarcinoma A549 cells and CAR-low ovarian
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carcinoma SKOV3 cell line [Fig. 2(a, b), Fig. S2], and
compared to HAdV-5. Luciferase activity upon the
transduction of SKOV3 cells was very similar for both
HAdV-56-Luc and HAdV-5-Luc, whilst HAdV-5-medi-
ated transgene expression in A549 cells was significantly
higher than that of HAdV-56 (Fig. 2a, b). The levels of
HAdV-56 luciferase activity in both cell lines were very
similar at all vector particles per cell (VP/cell) ratios tested
(~1.0107–2.2108RLU). Similar transduction experi-
ments were performed in CHO-K1- and CHO-CAR-
expressing cells. CAR receptor expression enhanced
HAdV-5 transgene levels, whilst it had little impact on the
overall levels of the HAdV-56 transduction of CHO cells
(Fig. 2c, d). Taken together, these data indicate that whilst
HAdV-5 avails of CAR-mediated entry, high levels of
CAR expression do not boost HAdV-56 transduction.
Sialic acid-containing glycans have previously been demon-
strated to be primary receptors for HAdV-D infection [12].
Here we examined the role of sialic acid in HAdV-56 bind-
ing and infection of human corneal epithelial cells using
neuraminidase to knockdown sialic acid residues. Whilst
blocking sialic acids did hinder HAdV-56 binding to the cell
surface initially, overall infection levels after an incubation
of 44 h were unaffected (Fig. 3a, b). Taken together, these
data suggest that, unlike other HAdV-D viruses, HAdV-56
does not require sialic acids as a primary receptor for effi-
cient infection.
Next, to examine the role of cellular integrins in HAdV-56
infection, we utilized CHO cells stably expressing a range of
different human integrins, including a4b1, a4b7, av, a2b1,
a3, a5, a6, a7, a8 and a9 subunits [21–27]. CHO-B2 (lack-
ing expression of the a5 subunit [28]) and CHO-K1
(expressing native a5) cell lines were used as negative
controls for these experiments. GFP-encoding HAdV-56
transduced CHO-a7 cells at substantially higher levels
(seven-fold greater) compared with the CHO control cells
(Fig. 3c, d), whilst there was no increase in the transduction
levels of HAdV-5 in these cells. This is the first example of
an Ad utilizing integrin-a7 as a potential entry receptor or
co-receptor. The levels of HAdV-56 transgene expression
were also significantly raised in av integrin-expressing
CHO cells. Taken together, these data indicate that integrin
subunit a7, and to a lesser extent subunit av, can function
as entry receptors or co-receptors for HAdV-56, thereby
adding to our knowledge of the diverse Ad family.
Previous studies have shown that integrin subunit a7 is
expressed at high levels in muscle tissue, including skeletal
and cardiac, as well as vascular, gastrointestinal and genito-
urinary smooth muscles [29, 30], suggesting that rHAdV-56
may be a candidate vector for vascular gene therapy or
intramuscular delivery applications. To test this, primary
human saphenous vein smooth muscle cells (HSVSMCs)
and human saphenous vein endothelial cells (HSVECs)
were isolated (n=3 individual patients), and the transduction
Fig. 1. HAdV-56 vector generation. (a) Schematic representation of the replication-deficient recombinant HAdV-56 vector construction
strategy using a three-plasmid system (pAdApt56.DE1.Luc, LacZ or GFP, pBr.HAdV-56.pIX.Hx and pBr.HAdV-56.DE3.ORF6.rITR) and
highlighting the regions involved in homologous recombination, the viral early (E) and late (L) genes. (b) Genome organization of the
recombinant HAdV-56 vector (rHAdV-56.DE1.DE3.5ORF6) expressing luciferase, GFP or LacZ genes.
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ability of HAdV-56-Luc was evaluated using these cells.
HAdV-56 mediated similar levels of luciferase transgene
expression at all of the VP/cell ratios tested to HAdV-5-Luc
(Fig. S3), indicating its potential for development as a vascu-
lar targeted vector.
HAdV-56 vector interactions with serum and
coagulation factors
Whilst HAdV-5-based vectors mediate high levels of gene
expression in vitro, they are severely compromised when it
comes to intravenous (i.v.) administration in vivo due to an
abundance of neutralizing antibodies and tropism-altering
interactions with blood components [31, 32]. As i.v. delivery
is the optimum and least invasive route for many clinical
applications, developing Ad types with good blood stability
is of significant interest.
We investigated the levels of pre-existing neutralizing anti-
bodies against HAdV-56 using a panel of serum samples
(n=103) taken from a cohort of healthy >50-year-old US
citizens. Whilst 57% of the serum samples exhibited high
levels of neutralizing activity (effective at dilutions >1 : 200)
against HAdV-5, less than half of these were inhibitory to
HAdV-56, i.e. 28% of serum samples neutralized HAdV-56
activity at dilutions >200 (Fig. 4a). Whilst HAdV-56 has
higher seroprevalence than the rare species B HAdV-35
(only 11% neutralized at 1 : 200 serum dilution), these data
indicate that antibodies against HAdV-56 are at substan-
tially lower levels in the general population than those
against HAdV-5.
The binding of many Ad types to human coagulation blood
factor X (FX) has a significant impact on virus transduction
in vitro and is a major determinant of tropism in vivo fol-
lowing i.v. administration [31, 33, 34]. We investigated
whether blood coagulation factors affect HAdV-56 trans-
duction. Physiological concentrations of human factor VII
(FVII), factor IX (FIX), factor X (FX) and protein C (PC)
were incubated with cells prior to the addition of HAdV-56
or HAdV-5 vectors. Unlike HAdV-5, HAdV-56 luciferase
reporter activity remained constant in A549 or SKOV3 cells
regardless of the addition of FVII, FIX, FX or PC (Fig. 4b,
c), thereby demonstrating that the transduction of HAdV-
56 is not augmented by any of the blood coagulation factors
tested.
Taken in combination, the lower seroprevalence and the
lack of influence from coagulation factors, indicates the
more favourable characteristics of HAdV-56 compared to
HAdV-5 for systemic delivery.
HAdV-56 biodistribution following i.v. delivery
in vivo
To characterize the HAdV-56 vectors following i.v. admin-
istration in vivo, we evaluated the biodistribution patterns
of HAdV-56-Luc using a previously described mouse
model [35, 36]. Vehicle (PBS) and HAdV-5-Luc-inoculated
animals were included in this study as negative and posi-
tive control groups, respectively. Half of the animals were
pretreated with clodronate liposomes (CL+) for macro-
phage depletion as they are known to play a major role in
HAdV-5 liver sequestration, and the rest of the mice were
Fig. 2. HAdV-56 transduction in vitro. HAdV-56-Luc transduction assay on (a) A549, (b) SKOV3, (c) CHO-K1 and (d) CHO-CAR cells in
comparison to HAdV-5-Luc.
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untreated (CL , intact macrophages). Two days after vec-
tor administration the animals were IVIS imaged and then
sacrificed, and several organs were collected and processed
for Ad DNA quantification and luciferase activity measure-
ments (Fig. 5a–c). On average, HAdV-5 and HAdV-56
mediated luciferase expression and the vector genome cop-
ies were 10-fold higher in CL+-treated animals compared
to the CL  groups. As expected, HAdV-5-derived
genomes and transgene expression were focused in the
liver and spleen. In both CL - and CL+-treated animals,
HAdV-56 DNA and luciferase transgene expression were
most abundant in the spleen, with low levels observed
in the lungs and pancreas, and liver transduction was
bypassed (Fig. 5a–c).
Elevation of the liver enzymes aspartate aminotransferase
(AST) and alanine aminotransferase (ALT) can be used as
an indicator of liver damage post-injection of Ad vectors.
In macrophage-depleted animals (CL+) injected with
HAdV-5-Luc, AST levels were significantly increased with
respect to clodronate-treated animals injected with vehicle
(PBS) or HAdV-56-Luc (P<0.05) (Fig. 5d), and in compar-
ison to non-depleted HAdV-5-injected animals. There
were no significant differences in ALT levels amongst any
of the groups. Serum aminotransferase elevation was not
observed in any of the HAdV-56-Luc-inoculated animals,
indicating reduced liver toxicity compared with HAdV-5
vectors.
HAdV-56 induces an inflammatory immune
response
Previous reports have demonstrated a potent inflammatory
immune response against Ad vectors in the hours following
i.v. administration. We investigated the levels of cytokines
and chemokines induced following i.v. delivery of PBS,
HAdV-56-Luc or HAdV-5-Luc by harvesting mouse serum
samples at 6 h post-i.v. administration of vectors and testing
the sera against a mouse multiplex panel. In the absence of
clodronate liposome treatment (CL ) HAdV-56-Luc
induced higher levels of pro-inflammatory mediators than
were observed in macrophage-depleted mice (CL+), and in
general these were elevated above the levels observed in
HAdV-5-Luc- or PBS-inoculated animals (Fig. 6). The
IFNg and tumour necrosis factor a (TNFa) levels were
higher in CL  animals treated with HAdV-56-Luc com-
pared to those treated with HAdV-5. The levels of cytokines
interleukin-5 (IL5) and IL6, and those of chemokines IP10,
MCP1 and MIG1, were significantly higher in HAdV-56-
injected animals in comparison to those for HAdV-5- or
PBS-administered controls. Such differences between the
vectors were not as marked in CL+ animals, and in fact the
retrieved IL6 was slightly higher in HAdV-5 mice compared
to those receiving HAdV-56. Conversely, with the exception
of IL6, the responses in HAdV-5 treated mice were largely
unaffected by the depletion of macrophages. Taken
together, these data indicate that rHAdV-56 triggers a
Fig. 3. HAdV-56 use of co-receptors. HAdV-56 binding to (a) and infection of (b) human corneal epithelial cells treated with and with-
out 20 mU ml 1 neuraminidase. Susceptibility of integrin-expressing CHO cells to HAdV-56-GFP and HAdV-5-GFP transduction; (c)
CHO-B2 and (d) CHO K1 cells were used as negative control cell lines. The results are presented as mean±SEM. Statistical significance
was determined by t-test and the Bonferroni post hoc test. Asterisks indicate the level of significance. *P <0.05, ***P <0.005 versus con-
trol cell lines.
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robust inflammatory and cellular immune response in vivo
following i.v. delivery.
HAdV-56 as a candidate vaccine vector
We next investigated the potential of HAdV-56 as a vaccine
vector candidate by performing prime immunizations in
Balb/c mice. Species D HAdV-26, a leading vaccine vector
that has recently been undergoing clinical trials for HIV and
Ebola [37, 38], was used for direct comparison in this study.
Mice were immunized intramuscularly with 1109VP or
11010VP of E1- and E3-deleted HAdV-26 vector express-
ing luciferase (HAdV-26-Luc) or HAdV-56-Luc. Two weeks
post prime immunization, the mice were sacrificed and the
serum titres against the HAdV-56 or HAdV-26 based vec-
tors were determined. The induction of Luc-specific IFNg-
producing cells was measured by IFNg ELISPOT after the
splenocytes were stimulated with a 15-mer peptide pool
spanning the luciferase protein. HAdV-56-Luc led to the
activation of luciferase-specific IFNg-producing cells, and
importantly this was to the same extent as that caused by
HAdV-26-Luc immunization (Fig. 7a). An antibody
response to the antigen could not be detected for either vec-
tor (data not shown). In contrast, there were neutralizing
antibodies against HAdV-56-Luc present in the serum of
the treated mice (Fig. 7b). This neutralizing activity was
similar for HAdV-26 in serum from HAdV-26-Luc animals.
Taken together, these data indicate that HAdV-56-Luc
induces luciferase-specific IFNg-producing cells and anti-
HAdV-56 neutralizing antibodies in Balb/c mice. Impor-
tantly, these effects are observed to the same extent as for
HAdV-26, the most clinically advanced human Ad vaccine
vector candidate.
DISCUSSION
To advance the use of Ads as therapeutic vectors it is crucial
to expand the repertoire of those available by studying rarer
types and creating efficient vector platforms. We present the
Fig. 4. HAdV-56 interaction with blood components. (a) HAdV-56, HAdV-35 and HAdV-5 seroneutralization by a cohort of healthy >50-
year-old US citizens (n=103 individual serum samples). Chart categorizing percentage of sera by neutralization titre. Neutralizing anti-
body titres were arbitrarily divided into the categories <16 (negative), 16–50, 50–200, 200–500, 500–1000 and >1000dilutions. (b, c)
HAdV-56-Luc transduction assay on (b) A549 and (c) SKOV3 cells in comparison to HAdV-5-Luc. Both were pre-incubated with blood
coagulation factors [factor VII (FVII), factor IX (FIX), factor X (FX) and protein C] before being added to cells. Statistical analysis was per-
formed by t-test with Welch’s correction: *P< 0.05, **P<0.0002 and ***P<0.0005.
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Fig. 5. HAdV-56 biodistribution in vivo. HAdV-56-Luc in vivo characterization in mice pre-treated or non-treated with clodronate lipo-
somes (CL+, CL ) to avoid macrophage capture of vectors. (a) Representative IVIS for viral biodistribution; (b) Ad genome units per tis-
sue; (c) vector transgene protein activity (luciferase) per tissue. (d) Liver damage state. Statistical comparison between groups was
made with a one-tailed t-test: #P<0.05 between HAdV-5 groups; *P<0.05 versus PBS and HAdV-56 CL+ groups, respectively.
Fig. 6. Cytokine profiles upon i.v. delivery of vectors. Cytokines were measured in blood samples from mice at 6 h following the
administration of PBS, HAdV-5-Luc and HAdV-56-Luc. Statistical analysis was performed using one-way ANOVA with Bonferroni’s mul-
tiple comparison test (IL-5, IP10, MCP-1), or by t-test comparison with Welch’s correction between not-treated-with-clodronate-lipo-
somes (CL ) HAdV-5 and HAdV-56 groups (IL-6 and MIG). In all cases: *P<0.05, **P<0.01 and ***P<0.005. No statistically significant
differences were observed in the others.
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first report on the generation of ease-of-use cloning systems
for HAdV-56 vectors and the initial characterization of in
vitro and in vivo profiles of the recombinant HAdV-56
reporter viruses.
Here, we created a flexible three-plasmid system for HAdV-
56 vector generation, allowing for the convenient insertion
of transgenes into a multiple cloning site substituting the E1
region. The wild-type (WT) HAdV-56 E4ORF6 region was
replaced with that of HAdV-5, a technique that was previ-
ously adopted for the generation of HAdV-26, HAdV-48
and HAdV-49 vectors, and enabled their successful produc-
tion in HAdV-5 E1-complementing cells [13, 15]. Interest-
ingly, we found that both HAdV-56 with the native ORF6
sequence and the HAdV-5 swap could be propagated on
HEK293 cells. However, for the vector with the native ORF6
transgene region, instability was observed for large trans-
gene insertions (in 1/10 plaques a truncated transgene
region was observed, as indicated by a smaller than expected
PCR product), with this being indicative of possible growth
problems for this vector (data not shown). HAdV-56-
HAdV-5-E4ORF6 allowed for high-quality manufacture at
high titres, making large-scale clinical manufacture a viable
option.
The efficacy of the frequently used HAdV-5 vector is ham-
pered in clinics by a combination of factors; anti-HAdV-5
immunity, its limited receptor usage, with cellular entry
highly dependent on CAR expression in vitro, binding to
blood factors directing liver tropism and related hepatotox-
icity in vivo. We found that HAdV-56 did not rely on CAR
for in vitro cell transduction at the level of HAdV-5, and
similarly to that reported for HAdV-26 and HAdV-48, it
was not affected by blood coagulation factors [31]. Previous
studies have demonstrated that HAdV-Ds can employ sub-
units of sialic acids and av integrins as entry receptors/
co-receptors [39]. The surprising observation from the
neuraminidase-mediated knockdown experiment that sialic
acids are not required for HAdV-56 infection of corneal
cells suggests that sialic acid-containing GD1a is not a main
receptor for HAdV-56, and instead this vector may possess
a unique/unusual primary receptor usage and entry path-
way. By screening a panel of integrin-expressing cells, we
identified a new candidate Ad entry receptor or co-receptor
and showed that HAdV-56 probably uses integrin-a7 for
cellular transduction in vitro. The observation that integrin-
a7 may be used as an entry receptor or co-receptor for Ad
is a new one, with previous work having mostly defined
roles for av-containing integrins [39]. Whilst we cannot
exclude the possibility that other integrins and/or other
molecules are also used as receptors/co-receptors by HAdV-
56, it is suggestive that HAdV-56 may have a somewhat
unique infection profile (Arnberg et al., manuscript in prep-
aration). More recently, a study demonstrated that HAdV-
37, another EKC inducer, uses aVb1 and a3b1 integrins
for the infection of human corneal epithelial cells [40]. In
this same piece of work, the expression of a2, a3, a6, aV,
b1 and b4 integrin subunits in the human corneal epithe-
lium was described, with significantly reduced or no expres-
sion of a4, a5, b3, or b5 integrins [40]. The expression of
integrins a7–9 was not investigated previously, but given
our new findings regarding HAdV-56 infection via a7, the
expression of this receptor on human corneal cells may also
be highly informative in the context on EKC.
The seroprevalence rate of HAdV-56 was lower than that
reported for HAdV-5 and in vivo liver targeting and hepa-
toxicity were absent, which are all beneficial factors for i.v.
delivery of vascular gene therapy vectors. It is worth noting
that the cohort of healthy volunteers used for the seropreva-
lence study were all 50+ years old, and this may have led to
slightly above average levels of neutralizing antibodies
against all vectors. Whilst HAdV-56 showed comparable
Fig. 7. Prime immunization with HAdV-56 in mice. Mice (n=6–7/group)
were immunized intramusculary with HAdV-26-empty (E, no trans-
gene), HAdV-26 or HAdV-56 vectors (1109VP or 11010VP) express-
ing luciferase protein (Luc). (a) Two weeks post-prime immunization,
the mice were sacrificed and the induction of Luc-specific IFNg-pro-
ducing cells was measured by IFNg ELISPOT; splenocytes were stimu-
lated with 15-mer peptide pool-spanning luciferase protein (Luc pool).
Each dot represents a mouse, the bar indicates the geometric mean
and the dotted line is the 95th percentile based on the medium control
samples. (b) The induction of anti-HAdV-56 or anti-HAdV-26 neutraliz-
ing antibodies was measured using a standard virus neutralization
assay. The dotted line corresponds to the titre of serum from non-vac-
cinated animals [log10(64)=1.81]. SFU, spot-forming units. Non-inferi-
ority statistical analysis was performed across dose, with HAd26.Luc
as the reference group and a pre-specified margin of 0.5 log10.
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levels of transduction in human vascular smooth muscle
and endothelial cells to HAdV-5, other Ad-Ds such as
HAdV-49, may be better suited to act as a cardiovascular
gene therapy for coronary interventions or bypass grafting
applications [41, 42]. This is mainly due to the fact that
upon ex vivo exposure to whole blood, HAdV-56 resulted in
the haemagglutination of both human and mouse blood
cells (Fig. S4), which raises questions over its suitability for
applications where this route of administration is necessary.
However, as our data suggest, HAdV-56 may have more
leverage as a vaccination vector. The induction of the potent
adaptive immunity required for successful vaccination vec-
tors is dependent on sufficient activation of the innate
immune system. Vaccine vectors benefit from complement
activation and the production and release of cytokines and
chemokines, including IL6, TNFa, IFNg, MCP1, IP10 and
MIP1, which are major players in the induction of anti-viral
immune responses. HAdV-56 induced higher levels of all
the aforementioned mediators, and it was significantly more
immunogenic than HAdV-5 following i.v. administration in
vivo. Whilst these factors may translate to Ad-associated
toxicity, making it unsuitable for intravascular delivery, it is
worth investigating its use as an intramuscularly delivered
vector. In the vaccine vector prime immunization assays
used in this study, HAdV-56 achieved the same levels of
immune induction as HAdV-26, with similar levels of lucif-
erase-specific IFNg-producing cells and similar production
of anti-Ad immunity. Clinical vaccines based on non-
human [43, 44] and human Ads are undergoing extensive
development, with exciting results being observed in studies
testing HAdV-26 against Ebola and HIV [37, 38, 45, 46]. In
preclinical tests, HAdV-26 used alone was demonstrated to
induce robust humoral and cellular immunity, while it has
also been well tolerated in humans while eliciting target spe-
cific immunity in phase I trials. Although it is beyond the
scope of this study, it would be interesting to investigate
HAdV-56 in a prime boost setting with HAdV-26 to see if
this could be successfully incorporated into such regimes.
Similar heterologous prime-boost strategies have demon-
strated increased potency and greater vaccine efficacy in
comparison to homologous prime boost approaches in a
range of clinical settings.
To summarize, in this study we have broadened the range
of available Ad vector types and have highlighted some of
the potential areas in which HAdV-56 could be of therapeu-
tic benefit.
METHODS
Cell lines
HEK293 (human embryonic kidney cells: ATCC CRL-1573)
were grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% foetal bovine serum
(FBS; Gibco, UK). A549 (human lung epithelial carcinoma:
ATCC CCL-185) and SKOV3 (human ovarian adenocarci-
noma: ATCC HTB-77) cells were grown in RPMI-1640,
supplemented with 10% FBS, 1% penicillin/streptomycin
(P/S), 1% L-glutamine (Gibco) and 1% Na-Pyr (Sigma,
UK). Chinese hamster ovary (CHO) cells, CHO-CAR,
CHO-B2, CHO-alpha v, CHO-alpha 4 beta7, CHO-alpha 4
beta1 and CHO-alpha 5 were maintained in DMEM con-
taining 10% FBS, L-glutamine, nonessential amino acids
and G418. CHO-K1, CHO-alpha 2 beta1, CHO-alpha 3,
CHO-alpha 6, CHO-alpha 7, CHO-alpha 8 and CHO-alpha
9 were grown in Ham’s F-12 medium (Invitrogen, Carlsbad,
CA, USA) containing 10% FBS, HEPES and 1%P/S.
Construction of replication-deficient recombinant
HAdV-56 vectors
The wild-type (WT) HAdV-56 virus, purchased from
ATCC, was propagated on HEK293 cells and purified by
caesium chloride (CsCl) density gradient centrifugation.
The 35 066 bp DNA sequence of WT HAdV-56 is available
on GenBank under accession no. HM770721.2.
HAdV-56 cloning system
The HAdV-56 vector construction strategy was based on a
three-plasmid system, with sufficient homology between
each of the plasmids to enable homologous recombination
in vitro following the co-transfection in HAdV-5 E1-com-
plementing HEK293 cells. Firstly, adapter plasmids
(pAdApt56.DE1) containing the left end of the HAdV-56
genome with E1 deletions, and incorporating either lucifer-
ase (pAdApt56.DE1.Luc), GFP (pAdApt56.DE1.GFP) or
LacZ (pAdApt56.DE1.LacZ) reporter genes, were generated.
Briefly, the plasmid pAdApt56.DE1 (nt 1–476 of WT
HAdV-56) contained the left inverted terminal repeat (ITR)
and included an expression cassette consisting of a CMV
promoter followed by a multiple cloning site, encompassing
Luc, GFP or LacZ within HindIII and XbaI sites, and the
SV40 poly(A) signal. This plasmid also contained WT
HAdV-56 nt 3369–5917 to allow homologous recombina-
tion in HEK293 cells, with the HAdV-56 pBr-based plasmid
(pBr.HAdV-56.pIX.Hx) carrying the HAdV-56 genome
from pIX to the hexon (nt 3755–19 308). The third plasmid
(pBr.HAdV-56.DE3.ORF6.rITR) contained the HAdV-56
genome from pVI to the right ITR (nt 17 333–35 066) and
had a 4 kb deletion in the E3 region, while the HAdV-5 E4-
ORF6 replaced the HAdV-56 E4-ORF6. The HAdV-56 E4-
ORF6 was exchanged by the HAdV-5 E4-ORF6 to enable
growth of the recombinant HAdV-56 vector on E1 comple-
menting cells as described previously [15]. Deletion of the
HAdV-56 E3 region and swapping of the HAdV-56 E4-
ORF6 for that of HAdV-5 was performed using the Gibson
assembly methodology [47]. Briefly, pBr.HAdV-56.DE3.
ORF6.rITR was constructed by generating two PCR frag-
ments flanking the HAdV-56 E3 region (nt 17 333–26 625
and 30 622–32 015) using primers to artificially introduce
complementary overhangs and allow the ligation of both
PCR fragments, thereby deleting ~4 kb of the HAdV-56 E3
region (nt 26 626–30 621). The HAdV-56 E4-ORF6
sequence from nt 32 016 to 33 221 was replaced by the cor-
responding sequence of HAdV-5 by generating two addi-
tional PCR fragments, one with the HAdV-5 E4-ORF6
(HAdV-5 GenBank accession no. M73260 nt 32 963–
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34 077) and another with the right arm of HAdV-56 (nt
33 222–35 066), again with artificially introduced comple-
mentary overhangs. Q5 high-fidelity DNA polymerase
(NEB) was used for all PCR reactions. The PCR fragments
(1 pmol total DNA) were incubated together at 50

C for 1 h
in the presence of 10 µl Gibson assembly master mix (NEB),
and this was followed by transformation in 10-beta compe-
tent E. coli (NEB).
HAdV-56 plasmid transfection, amplification and
titre quantification
Reconstitution of the full-length recombinant HAdV-56
vector (rHAdV-56.DE1.DE3.5ORF6 or rHAdV-56 for short)
expressing luciferase, GFP or b-galactosidase (LacZ) was
accomplished by homologous recombination via co-trans-
fection of pAdApt56.DE1.Luc/GFP/LacZ, pBr.HAdV-56.
pIX.Hx and pBr.HAdV-56.DE3.ORF6.rITR in HEK293 cells
using Lipofectamine 2000 (Invitrogen). Following cytopath-
ogenic effect, HAdV-56 vectors were harvested and further
propagated on HEK293 cells. Purified HAdV-56 vectors
were obtained by two-step CsCl gradient centrifugation
[48]. Whole viral genomes were fully sequenced at Glasgow
Polyomics by NGS with Illumina adapters. Viruses were
also verified by silver stain analysis and Western blot using
the anti-fibre 4D2 antibody (1 : 500 dilution). Virus particle
titres were determined by OD260 measurement in the pres-
ence of SDS. Viral infectious units were determined by
TCID50 analysis. The VP:PFU ratios were in the range of
1 : 200–285 for all vectors. In all of the experiments the
HAdV-56 performance was compared to that of Ad vectors
that expressed the same recombinant reporter gene under
the control of the same regulatory sequences.
HAdV-56 vector manufacture
HEK293 suspension cells were seeded at a cell density of
1.5106 cellsml 1 in 125ml shaker flasks in a total volume
of 15ml EX-CELL 293, AEM, CD293, CDM4-HEK293,
SFM4-HEK293 or EX-CELL GTM-3 medium. The cells
were subsequently infected with HAdV-56 (270 VP/cell)
and incubated at 110 rpm, 8% CO2, 37
C. The harvest was
performed at day 3 post-infection (p.i.) and the infectious
virus yield was determined by TCID50 analysis.
To investigate different purification methods, CsCl purified
virus was first spiked in spent medium of HEK293 cells to
determine the retention time of the virus peak after purifica-
tion using Mustang Q, Poros HQ or Monolith QA chroma-
tography. The virus yield after this purification step was
determined by TCID50. To obtain a scalable process,
HEK293 suspension cells were seeded at a cell density of
1.5106 cellsml 1 in shaker flasks using EX-CELL 293
medium, and infected with HAdV-56 (270 VP cell 1). At
day 3 p.i., a crude harvest was obtained, treated with benzo-
nase and subsequently purified using the same linear gra-
dients as the initial spike experiments to confirm the
previous findings. The fraction containing the viral peak
was determined and subsequently step gradients were per-
formed on all AIEX purifications using a step after loading
for the elution of contaminants and a step with a higher salt
concentration for the elution of the viral peak. The obtained
materials were tested for purity using SDS-PAGE.
Viral transduction assays
The cells were seeded at 1104 cells well 1. The following
day monolayers were washed with PBS and viral vectors
were added at the indicated VP/cell concentrations in their
corresponding media without serum. After 3 h at 37

C, the
medium was replaced with 200 µl well 1 of medium supple-
mented with 10% FBS, and the cells were incubated for a
further 48 h. In the experiments in which blood coagulation
factors were used, these were pre-incubated with the vectors
for 30min at 37

C before they were added to the cells. The
blood coagulation factors were purchased from Cambridge
Bioscience and used at physiological concentrations: FVII
at 0.5 µgml 1, FIX at 5 µgml 1, FX at 10 µgml 1 and pro-
tein C at 4.5 µgml 1. For the assay readout, the plates were
washed and the cells lysed with 1 reporter lysis buffer
(100 µl per well; Promega) and one freeze-thaw cycle was
performed. Luciferase (Luciferase assay system, Promega)
and BCA protein quantitation assays (ThermoFisher Scien-
tific) were performed with 10 µl of lysed cells in white opa-
que plates (Greiner BioOne) following the manufacturer’s
instructions and the results were recorded in a Victor X
multilabel plate reader (Perkin-Elmer). Luciferase activity
was normalized to the total protein content of the sample
wells and transduction was calculated as a percentage of the
control. The transduction level was expressed as lumines-
cence relative light units per mg of protein per well (RLU
mg 1). All of the assays were performed in triplicate.
Sialic acid receptor studies
HAdV-56 binding
Metabolically 35S-labelled HAdV-56 virions were produced
in A549 cells as described previously [49], with some minor
modifications, i.e. the elution was performed in phosphate-
buffered saline (PBS) using a NAP column (GE Healthcare).
Human corneal epithelial (HCE) cells were grown in SHEM
media [SHEM media: 1 : 1; DMEM and Ham’s F12 nutrient
mixture supplemented with 20mM HEPES, 5 µgml 1 insu-
lin, 0.5 % DMSO, 0.1 µgml 1 cholera toxin, 10 ngml 1
hEGF, PEST (20Uml 1 penicillin + 20 gml 1 streptomy-
cin) and 10% FCS]. The cells were detached with pre-
warmed PBS containing 0.05% EDTA, reactivated in
growth medium for 1 h at 37

C (in suspension). The cells
were then pelleted in a V-bottom 96-well plate (1105 cells
well 1) and washed once with binding buffer (BB) [BB:
DMEM supplemented with 20mM HEPES, PEST and 1%
bovine serum albumin (BSA)]. The cells were treated with
or without neuraminidase (20 mU ml 1, Vibrio cholerae
neuraminidase; Sigma) for 1 h at 37

C before being incu-
bated with virions. The cells were washed twice with BB to
remove the neuraminidase. Metabolically 35S-labelled
HAdV-56 virions (109VP well 1) diluted in BB were added
to the cells and incubated for 1 h at 4

C on ice. To get rid of
unbound virions, the cells were washed twice with PBS.
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Cell-associated radioactivity was measured using a Wallac
1409 liquid scintillation counter (Perkin-Elmer).
HAdV-56 infection
HCE cells were grown as a monolayer in a transparent flat-
bottom 96-well plate (3 0 000 cells well 1). The cells were
then washed twice with serum-free growth medium
(SFGM). The cells were treated with or without neuramini-
dase (20 mU ml 1) for 1 h at 37

C. The cells were washed
twice with SFGM to remove the neuraminidase. WT
HAdV-56 virions were added to the cells and incubated for
1 h on ice. To get rid of unbound virions the cells were
washed thrice with SFGM. The cells were incubated for 44 h
at 37

C in culture medium containing 1% FBS. After 44 h
incubation, the cells were washed once with PBS (pH 7.4)
and fixed with ice-cold methanol at  20

C. The cells were
then stained with mouse monoclonal anti-HAdV hexon
antibody diluted in PBS (1 : 200) for 1 h at room tempera-
ture (RT). The cells were washed thrice with PBS and incu-
bated for 1 h with Alexa Fluor-488-conjugated secondary
antibody (1 : 1000) diluted in PBS at RT. The cells were also
stained with DAPI (1 : 5000) diluted in PBS for another 5
min. After the cells were washed thrice with PBS, the num-
ber of infected cells was counted in Trophos (Luminy Bio-
tech Enterprises).
Integrin co-receptor usage assays
The cells (CHO, CHO-B2, CHO-alpha v, CHO-alpha 4
beta7, CHO-alpha 4 beta1, CHO-alpha 5, CHO-K1, CHO-
alpha 2 beta1, CHO-alpha 3, CHO-alpha 6, CHO-alpha 7,
CHO-alpha 8 and CHO-alpha 9) were plated in duplicate
wells in 96-well tissue culture plates and transduced with
HAdV-5-GFP (3.7104VP cell 1) and HAdV-56-GFP
(1.2104VP cell 1). The cultures were maintained at 37

C
in a humidified atmosphere with 5% CO2. At 24 h after
infection, automated fluorescent image acquisition was per-
formed for each individual well of a 96-well plate using
Trophos Plate RUNNER HD (Trophos, Marseille, France).
The images acquired from the wells were analysed using
Tina software (Trophos).
HAdV-56 seroneutralization
Serological inhibition of HAdV-56-Luc, HAdV-35-Luc and
HAdV-5-Luc transduction was evaluated over a collection
of 103 serum samples from a cohort of healthy >50-year-old
US citizens. Seroneutralization assays were performed using
the protocol described in Sprangers et al. [50]. Briefly,
serum samples were heat-inactivated at 56

C for 60min,
and then twofold dilutions were performed in a 96-well tis-
sue culture plate. The dilutions covered a range from 1/16
to 1/4 096 in an end volume of 50 µl DMEM. Negative con-
trols consisted of DMEM alone. We added 50 µl of virus
solution (1108VPml 1) to each well. Next, a cell suspen-
sion (104 A549 cells) was added to the well to a final volume
of 200 ul. Following 24 h incubation, the luciferase activity
in the cells was measured using a Steady-Glo luciferase
reagent system (Promega). The neutralization titres were
defined as the maximum serum dilution that neutralized
90% of luciferase activity.
In vivo biodistribution
All animal experimentation was approved by the University
of Glasgow Animal Procedures and Ethics committee and
was performed under UK Home Office license in strict
accordance with UK Home Office guidelines. Male outbred
MF1 immunocompetent mice aged between 7–9weeks
(Harlan, Blackthorn, UK) were used. The animals were
organized in six groups with five animals in each group. To
deplete macrophages, 200 µl of clodronate-encapsulated lip-
osomes (www.clodronateliposomes.org) was administered
i.v. to half of the groups 48 h before the administration of
the vectors. Intravenous injections were performed via the
tail lateral vein. On day 0, treatment groups were i.v.
injected with 51010VP of HAdV-56-Luc or HAdV-5-Luc
diluted in 100 µl PBS. Matched control groups were injected
with 100 µl PBS at the same time-point. Blood was taken at
6 h post-vector delivery and the serum was separated as pre-
viously described [30]. Cytokine/chemokine profiles were
determined from 6 h post-injection sera (>60 µl) using a
mouse cytokine multiplex assay kit (Invitrogen) and a
Luminex machine (Luminex Corporation). At 48 h post-
delivery of vectors, the animals were sacrificed and their liv-
ers, spleens, lungs, kidney, pancreases and hearts collected
for the quantification of viral genomes by the amplification
of the transgene region promoter with CMV primers and
the measurement of luciferase activity as described previ-
ously [51]. Blood was also collected at the end point, and
the serum was segregated (80 µl) and used for the quantifi-
cation of the transaminases ALT and AST as previously
described [35].
Mouse immunization study
All animal experimentation was performed according to
Dutch law and the Guidelines on the Protection of Experi-
mental Animals published by the Council of the European
Committee. Six-to-eight-week-old specific pathogen-free
female Balb/c mice were purchased from Charles River and
kept at the institutional animal facility under specified path-
ogen-free conditions. For prime immunization studies mice
were immunized intramuscularly with HAdV-56 or HAdV-
26 vectors (1109VP or 11010VP mouse 1) expressing
Luc. Two weeks post-immunization, mice were sacrificed
and the induction of Luc-specific IFNg-producing cells was
measured by IFNg ELISPOT. In brief, mouse splenocytes
were stimulated with 15-mer peptide pool spanning Luc
(luc pool), medium (control negative) or phorbol myristate
acetate (PMA; positive control). For the presentation of data
each dot on the graph represents a mouse, the bar indicates
the geometric mean and the dotted line is the 95th percen-
tile based on the medium control samples. The induction of
anti-HAdV-56 neutralizing antibodies was measured using
a standard virus neutralization assay as mentioned above,
but the dilutions tested ranged from 1/64 down to 1/16 384
[50]. The dotted line on the graph corresponds to the log10
of the highest serum concentration used [log10(64)=1.81].
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Statistical analysis
Statistical analysis was performed with GraphPad Prism
software. One-way ANOVA with the Bonferroni post-hoc
test was used for comparisons between more than two
groups, whereas statistical comparison between two groups
was made using a t-test. The parameters of significance are
indicated in each figure caption: *P<0.05, **P<0.005,
***P<0.001 and NS, not statistically significant, P>0.05. The
presented in vitro results are averaged data from at least
three different experiments with three experimental repli-
cates per condition. The in vivo experiments were per-
formed with a minimum of five animals per group. All of
the errors bars represent the standard error of the mean
(SEM). For Fig. 7a statistical analyses were performed with
SAS version 9.4. Non-inferiority testing across dose was per-
formed on log10-transformed data, with HAdV-26-Luc as a
reference and a pre-specified margin of 0.5 log.
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